CStone Pharmaceuticals (HKEX: 2616) has completed its geographic rollout of sugemalimab by signing an exclusive commercialization agreement with Arrotex Pharmaceuticals for Australia and New Zealand, the fifth and final major territory in its out-licensing campaign for the approved anti-PD-L1 antibody. The deal extends sugemalimab's commercial footprint to more than 60 countries and regions, completing a hub-and-spoke licensing model that CStone has assembled since regaining ex-China rights to the drug in 2023. Financial terms were not disclosed.
Under the agreement, Arrotex will hold exclusive commercialization rights for sugemalimab across all approved and future indications in both territories, including stage III and IV non-small cell lung cancer (NSCLC), gastric cancer, esophageal squamous cell carcinoma, and extranodal NK/T-cell lymphoma, subject to regulatory approval by Australia's Therapeutic Goods Administration (TGA). Arrotex will be responsible for TGA and Medsafe regulatory submissions. CStone will supply sugemalimab to Arrotex and recognize a profit-share arrangement, in addition to receiving an undisclosed upfront payment and being eligible for regulatory and commercial milestone payments.
Deal context
Sugemalimab (Cejemly) is a fully human, full-length IgG4 monoclonal antibody that blocks the PD-1/PD-L1 checkpoint interaction. The European Commission approved sugemalimab in July 2024 for first-line metastatic NSCLC, and the UK's MHRA followed with the same indication in October 2024. In February 2026, the MHRA granted a second indication for unresectable stage III NSCLC consolidation therapy following chemoradiotherapy — a setting where sugemalimab is now one of only two approved PD-(L)1 inhibitors in Europe and the UK, alongside AstraZeneca's durvalumab (Imfinzi). China's National Medical Products Administration has approved the drug for five indications.
Arrotex is the pharmaceutical commercialization platform of DBG Health, Australia's largest diversified healthcare group. DBG Health is privately held but attracted a significant minority investment from US-based private equity firm BDT and MSD Partners in 2025. Arrotex describes itself as Australia's largest pharmaceutical company by prescription volume, supplying approximately 50% of the country's total prescription medicine volume.